Supreme Court Upholds Medicare Drug Price Negotiation, Dealing Setback to Bristol-Myers Squibb, Amgen, and AbbVie
The US Supreme Court has ruled against the pharmaceutical industry's challenge to the Biden-era Medicare Drug Price Negotiation Program, cementing the government's authority to mandate price reductions on high-cost drugs, with Bristol-Myers Squibb, Amgen, and AbbVie among the companies most exposed to negotiated price cuts on key products.
The Court's Decision and What It Settles
The US Supreme Court has handed a significant defeat to the pharmaceutical industry by upholding the Medicare Drug Price Negotiation Program, a provision of the Inflation Reduction Act that gives the US government authority to directly negotiate prices for certain high-cost drugs sold to Medicare patients. The ruling ends a legal challenge mounted by several major pharmaceutical companies and trade groups who argued the programme violated constitutional protections.
With the court's backing, the programme's framework is now legally settled. The Centers for Medicare and Medicaid Services can proceed with price negotiation cycles as structured, applying mandatory discounts to drugs selected for negotiation based on their expenditure impact on the Medicare programme. For pharmaceutical companies with large-selling Medicare drugs, the ruling removes the last major legal backstop against mandated price reductions.
Who Faces the Most Direct Exposure
The drug price negotiation programme targets products with high Medicare Part D spending. Among companies in the programme's initial negotiation cycles:
Bristol-Myers Squibb markets Eliquis, a widely prescribed blood thinner that is among the highest-expenditure drugs in Medicare. Eliquis was included in the first round of negotiations. A mandated price cut on Eliquis directly compresses revenue from a product that has been a cornerstone of BMY's commercial portfolio.
Amgen markets Enbrel, a top-selling biologic for rheumatoid arthritis and other inflammatory conditions. Enbrel was also included in the initial negotiation tranche. Although Amgen has been managing Enbrel's biosimilar competition separately, a Medicare-negotiated price reduction adds an additional top-line pressure on the drug's contribution to earnings.
AbbVie markets Imbruvica, a blood cancer treatment included in early negotiation rounds. AbbVie has also been transitioning its revenue base toward newer products including Skyrizi and Rinvoq, both of which could become negotiation targets in future cycles as their Medicare expenditure increases.
The Longer-Run Implications for Drug Pricing
The Supreme Court ruling does not simply resolve the current negotiation cycle; it establishes the legal foundation for the programme to expand to more drugs in future years. Under the programme's design, the number of drugs eligible for negotiation increases over time, gradually extending the government's pricing authority across the Medicare formulary.
For pharmaceutical companies, this represents a structural shift in the operating environment. The drug-pricing premium that US manufacturers have historically received relative to other markets is being compressed through a new mechanism that operates independently of patent expiry or generic competition. Companies will need to incorporate Medicare pricing risk into drug development and acquisition economics going forward.
Context and Outlook
The pharmaceutical industry's legal strategy against the programme has been exhausted at the Supreme Court level. Companies may pursue legislative avenues or engage in advocacy for programme modifications, but the immediate practical implication is that the negotiation framework proceeds as designed. For investors tracking Bristol-Myers Squibb, Amgen, and AbbVie, the ruling confirms a revenue headwind that had been held in legal uncertainty.
Sources
Frequently asked questions
What did the Supreme Court rule on Medicare drug price negotiation?
The Supreme Court upheld the Medicare Drug Price Negotiation Program, rejecting pharmaceutical companies' constitutional challenge and affirming the government's authority to mandate price reductions on high-cost Medicare drugs.
Which drugs are subject to Medicare price negotiation?
The initial negotiation round targeted ten high-expenditure drugs including Eliquis (Bristol-Myers Squibb), Enbrel (Amgen), and Imbruvica (AbbVie), among others. Future negotiation cycles will add more drugs over time.
How does the negotiated price affect pharmaceutical company revenue?
Negotiated prices apply to drugs sold through Medicare Part D, reducing per-unit revenue from one of the largest drug purchasers in the United States. The magnitude of the impact depends on how much of a drug's sales flow through Medicare and the depth of the negotiated discount.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track BMY free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.
Follow all 3 stocks in this story as one aggregated read with Pro.